Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
摘要:
Pharmacokinctic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential. (c) 2007 Elsevier Ltd. All rights reserved.
[EN] INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE I INTERAGISSANT AVEC LE RÉCEPTEUR POUR LE TRAITEMENT D'UNE MALADIE
申请人:UNIV TEXAS
公开号:WO2021046515A1
公开(公告)日:2021-03-11
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1 -mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
Transition-Metal-Free Synthesis of Benzimidazoles Mediated by KOH/DMSO
作者:Hannah Baars、Astrid Beyer、Stefanie V. Kohlhepp、Carsten Bolm
DOI:10.1021/ol403414v
日期:2014.1.17
Benzimidazoles are prepared by intramolecular N-arylations of amidines mediated by potassium hydroxide in DMSO at 120 degrees C. In this manner, diversely substituted products have been obtained in moderate to very good yields.